Laxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), Laxatol


Buy Laxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), LaxatolCheap Laxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), LaxatolOrder Laxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), LaxatolLaxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), Laxatol Online No PrescriptionLaxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), Laxatol Online NowLaxido Orange, Powder For Oral Solution - Summary Of Product Characteristics (Spc), Laxatol Without Prescriptions
Customer reviews
Vaka
I NRA) is a good idea.
jester-girl
Improve your sexual life and enjoy real men’s power!
DjProof
Sorry for that I interfere ... I have a similar situation. I invite to discussion. Write here or in PM.
myXaaa
If the man’s health is normal, erections should be automatic, my ex-wife used to tell me. Rubbish!
Mazimo
ne.ne for me
Sekas
Thanks for the interesting stuff!
dAshka
Blog super, everything would be different!

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www. mhra. gov. uk/yellowcard

Severe distension or pain can be treated using nasogastric aspiration. Vomiting or diarrhoea may induce extensive fluid loss, possibly leading to electrolyte disturbances that should be treated appropriately.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Osmotically acting laxatives.

ATC code: A06A D65

Macrogol 3350 induces a laxative effect through its osmotic action in the gut. This product also contains electrolytes to ensure that there is no overall gain or loss of water, potassium or sodium.

Clinical studies using the listed active substances for the treatment of chronic constipation have shown that the dose required to produce normally formed stools tends to decrease over time. For most patients, the maintenance dose will be one to two sachets per day (adjusted according to individual response).

Comparative studies in faecal impaction using active controls (e. g. enemas) have not been performed. However, results from a non-comparative study have shown that, from a population of 27 adult patients, the listed combination of active substances cleared faecal impaction in 12/27 (44%) patients after one day's treatment, increasing to 23/27 (85%) following two days' treatment and 24/27 (89%) recovered at the end of three days.

5.2 Pharmacokinetic properties

Macrogol 3350 is virtually unabsorbed from the gastro-intestinal tract and is excreted, unaltered, in faeces. Any macrogol 3350 that enters the systemic circulation is excreted in urine.

5.3 Preclinical safety data

Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential, based on conventional studies of pharmacology, repeated dose toxicity and genotoxicity.

There were no direct embryotoxic or teratogenic effects in rats even at maternally toxic levels that are a multiple of 66 x the maximum recommended dose in humans for chronic constipation and 25 x for faecal impaction. Indirect embryofetal effects, including reduction in fetal and placental weights, reduced fetal viability, increased limb and paw hyperflexion and abortions, were noted in the rabbit at a maternally toxic dose that was 3.3 x the maximum recommended dose in humans for treatment of chronic constipation and 1.3 x for faecal impaction. Rabbits are a sensitive animal test species to the effects of GI-acting substances and the studies were conducted under exaggerated conditions with high dose volumes administered, which are not clinically relevant. The findings may have been a consequence of an indirect effect of macrogol 3350 related to poor maternal condition as the result of an exaggerated pharmacodynamic response in the rabbit. There was no indication of a teratogenic effect.

There are long-term animal toxicity and carcinogenicity studies involving macrogol 3350. Results from these and other toxicity studies using high levels of orally administered high molecular weight macrogols provide evidence of safety at the recommended therapeutic dose.

6. Pharmaceutical particulars

6.1 List of excipients

Acesulfame Potassium (E950)